The global hemoglobinopathies drugs market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of thalassemia and sickle cell disease, rising awareness about the diseases, and technological advancements in drug development.
The global hemoglobinopathies drugs market is segmented on the basis of type into thalassemia therapy and sickle cell disease (SCD) therapy; on the basis of application into alpha thalassemia, beta thalassemia, sickle cell disease (SCD), Hb variants diseases; and on the basis of region into North America, Latin America, Europe, Asia Pacific and Middle East & Africa. The North American region dominates this market with a share of over 40%. This can be attributed to high prevalence rates for these diseases in this region as well as increased awareness among people about these disorders.
Some Of The Growth Factors Of This Market:
- Increasing prevalence of Hemoglobinopathies Drugs in developing countries such as India and China is one of the major factors driving the growth of this market.
- Increasing awareness about Hemoglobinopathies Drugs among people and physicians is also driving the growth of this market.
- The increasing number of clinical trials for new drugs in this segment are also contributing to the growth of this market.
- Increasing government initiatives for research and development activities are also contributing to the growth of this market.
Industry Growth Insights published a new data on “Hemoglobinopathies Drugs Market”. The research report is titled “Hemoglobinopathies Drugs Market research by Types (Thalassemia Therapy, Sickle Cell Disease(SCD) Therapy, Other Therapy), By Applications (Alpha Thalassemia, Beta thalassemia, Sickle Cell Disease, Hb Variants Diseases), By Players/Companies Gamida Cell, Alnylam Pharmaceuticals, Biogen Idec, Sangamo BioSciences Inc., Genetix Pharmaceuticals/Bluebird Bio, Global Blood Therapeutics Inc., Pfizer Inc., Mast Therapeutics, Emmaus Life Sciences, Inc., Prolong Pharmaceuticals, Celgene Corporation, HemaQuest Pharmaceuticals”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Hemoglobinopathies Drugs Market Research Report
By Type
Thalassemia Therapy, Sickle Cell Disease(SCD) Therapy, Other Therapy
By Application
Alpha Thalassemia, Beta thalassemia, Sickle Cell Disease, Hb Variants Diseases
By Companies
Gamida Cell, Alnylam Pharmaceuticals, Biogen Idec, Sangamo BioSciences Inc., Genetix Pharmaceuticals/Bluebird Bio, Global Blood Therapeutics Inc., Pfizer Inc., Mast Therapeutics, Emmaus Life Sciences, Inc., Prolong Pharmaceuticals, Celgene Corporation, HemaQuest Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Hemoglobinopathies Drugs Market Report Segments:
The global Hemoglobinopathies Drugs market is segmented on the basis of:
Types
Thalassemia Therapy, Sickle Cell Disease(SCD) Therapy, Other Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Alpha Thalassemia, Beta thalassemia, Sickle Cell Disease, Hb Variants Diseases
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Gamida Cell
- Alnylam Pharmaceuticals
- Biogen Idec
- Sangamo BioSciences Inc.
- Genetix Pharmaceuticals/Bluebird Bio
- Global Blood Therapeutics Inc.
- Pfizer Inc.
- Mast Therapeutics
- Emmaus Life Sciences, Inc.
- Prolong Pharmaceuticals
- Celgene Corporation
- HemaQuest Pharmaceuticals
Highlights of The Hemoglobinopathies Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Thalassemia Therapy
- Sickle Cell Disease(SCD) Therapy
- Other Therapy
- By Application:
- Alpha Thalassemia
- Beta thalassemia
- Sickle Cell Disease
- Hb Variants Diseases
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hemoglobinopathies Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hemoglobinopathies are a group of diseases that affect the structure or function of hemoglobin, a protein in the blood. Hemoglobinopathies can cause anemia (low levels of red blood cells), and can lead to serious health problems if not treated. Some common hemoglobinopathies include sickle cell disease, thalassemia, and beta-thalassemia.
Some of the major companies in the hemoglobinopathies drugs market are Gamida Cell, Alnylam Pharmaceuticals, Biogen Idec, Sangamo BioSciences Inc., Genetix Pharmaceuticals/Bluebird Bio, Global Blood Therapeutics Inc., Pfizer Inc., Mast Therapeutics, Emmaus Life Sciences, Inc., Prolong Pharmaceuticals, Celgene Corporation, HemaQuest Pharmaceuticals.
The hemoglobinopathies drugs market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hemoglobinopathies Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Hemoglobinopathies Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Hemoglobinopathies Drugs Market - Supply Chain
4.5. Global Hemoglobinopathies Drugs Market Forecast
4.5.1. Hemoglobinopathies Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Hemoglobinopathies Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Hemoglobinopathies Drugs Market Absolute $ Opportunity
5. Global Hemoglobinopathies Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Hemoglobinopathies Drugs Market Size and Volume Forecast by Type
5.3.1. Thalassemia Therapy
5.3.2. Sickle Cell Disease(SCD) Therapy
5.3.3. Other Therapy
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Hemoglobinopathies Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Hemoglobinopathies Drugs Market Size and Volume Forecast by Application
6.3.1. Alpha Thalassemia
6.3.2. Beta thalassemia
6.3.3. Sickle Cell Disease
6.3.4. Hb Variants Diseases
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Hemoglobinopathies Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Hemoglobinopathies Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Hemoglobinopathies Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Hemoglobinopathies Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Hemoglobinopathies Drugs Demand Share Forecast, 2019-2026
9. North America Hemoglobinopathies Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Hemoglobinopathies Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Hemoglobinopathies Drugs Market Size and Volume Forecast by Application
9.4.1. Alpha Thalassemia
9.4.2. Beta thalassemia
9.4.3. Sickle Cell Disease
9.4.4. Hb Variants Diseases
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Hemoglobinopathies Drugs Market Size and Volume Forecast by Type
9.7.1. Thalassemia Therapy
9.7.2. Sickle Cell Disease(SCD) Therapy
9.7.3. Other Therapy
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Hemoglobinopathies Drugs Demand Share Forecast, 2019-2026
10. Latin America Hemoglobinopathies Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Hemoglobinopathies Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Hemoglobinopathies Drugs Market Size and Volume Forecast by Application
10.4.1. Alpha Thalassemia
10.4.2. Beta thalassemia
10.4.3. Sickle Cell Disease
10.4.4. Hb Variants Diseases
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Hemoglobinopathies Drugs Market Size and Volume Forecast by Type
10.7.1. Thalassemia Therapy
10.7.2. Sickle Cell Disease(SCD) Therapy
10.7.3. Other Therapy
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Hemoglobinopathies Drugs Demand Share Forecast, 2019-2026
11. Europe Hemoglobinopathies Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Hemoglobinopathies Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Hemoglobinopathies Drugs Market Size and Volume Forecast by Application
11.4.1. Alpha Thalassemia
11.4.2. Beta thalassemia
11.4.3. Sickle Cell Disease
11.4.4. Hb Variants Diseases
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Hemoglobinopathies Drugs Market Size and Volume Forecast by Type
11.7.1. Thalassemia Therapy
11.7.2. Sickle Cell Disease(SCD) Therapy
11.7.3. Other Therapy
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Hemoglobinopathies Drugs Demand Share, 2019-2026
12. Asia Pacific Hemoglobinopathies Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Hemoglobinopathies Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Hemoglobinopathies Drugs Market Size and Volume Forecast by Application
12.4.1. Alpha Thalassemia
12.4.2. Beta thalassemia
12.4.3. Sickle Cell Disease
12.4.4. Hb Variants Diseases
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Hemoglobinopathies Drugs Market Size and Volume Forecast by Type
12.7.1. Thalassemia Therapy
12.7.2. Sickle Cell Disease(SCD) Therapy
12.7.3. Other Therapy
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Hemoglobinopathies Drugs Demand Share, 2019-2026
13. Middle East & Africa Hemoglobinopathies Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Hemoglobinopathies Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Hemoglobinopathies Drugs Market Size and Volume Forecast by Application
13.4.1. Alpha Thalassemia
13.4.2. Beta thalassemia
13.4.3. Sickle Cell Disease
13.4.4. Hb Variants Diseases
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Hemoglobinopathies Drugs Market Size and Volume Forecast by Type
13.7.1. Thalassemia Therapy
13.7.2. Sickle Cell Disease(SCD) Therapy
13.7.3. Other Therapy
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Hemoglobinopathies Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Hemoglobinopathies Drugs Market: Market Share Analysis
14.2. Hemoglobinopathies Drugs Distributors and Customers
14.3. Hemoglobinopathies Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Gamida Cell
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Alnylam Pharmaceuticals
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Biogen Idec
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Sangamo BioSciences Inc.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Genetix Pharmaceuticals/Bluebird Bio
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Global Blood Therapeutics Inc.
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Pfizer Inc.
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Mast Therapeutics
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Emmaus Life Sciences, Inc.
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Prolong Pharmaceuticals
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Celgene Corporation
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. HemaQuest Pharmaceuticals
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
